Table 2.
Incremental viraemic infections in 2030, missed diagnoses and treatments (2020–2030), and cumulative (2020–2030) excess incident HCV, HCC, and LRDs, by WHO region and World Bank Income Group under the 1-year delay scenario.
| Region | Incremental, 2030 |
Missed interventions, 2020–2030 |
Excess cases, 2020–2030 |
|||
|---|---|---|---|---|---|---|
| Viraemic infections | New diagnoses | Treatment starts | Incident HCV | Incident HCC | LRDs | |
| WHO region | ||||||
| African | 12,300 | –47,100 | –15,700 | 2,600 | 850 | 1,700 |
| Eastern Mediterranean | 217,000 | –222,000 | –242,000 | 47,900 | 9,800 | 15,800 |
| European | 96,900 | –142,000 | –130,000 | 15,800 | 8,700 | 13,800 |
| American | 68,300 | –105,000 | –103,000 | 4,500 | 10,200 | 14,800 |
| South-East Asia | 73,100 | –104,000 | –81,600 | 20,300 | 3,600 | 7,900 |
| Western Pacific | 155,000 | –285,000 | –174,000 | 30,000 | 11,700 | 18,200 |
| World Bank Income Group | ||||||
| High income | 150,000 | –131,000 | –209,000 | 18,100 | 20,000 | 29,900 |
| Upper-middle income | 174,000 | –406,000 | –196,000 | 33,700 | 10,200 | 15,400 |
| Lower-middle income | 285,000 | –317,000 | –322,000 | 66,200 | 13,700 | 25,100 |
| Low income | 14,400 | –51,400 | –18,300 | 3,200 | 920 | 1,800 |
| Global | 623,000 | –906,000 | –746,000 | 121,000 | 44,800 | 72,200 |
HCC, hepatocellular carcinoma; LRDs, liver-related deaths.